Blissel® is specifically formulated to meet the needs of women with vaginal atrophy

Click to play our How to use an applicator video.
Click to watch our How to use an applicator video.

Prescribing and adverse event reporting information can be found at the end of this video.

Blissel® has been designed with women in mind- to help avoid mess and give treatment for vaginal atrophy (VA) in comfort, an applicator is provided.1

Blissel® can be prescribed for the treatment of VA in postmenopausal women who are not currently receiving systemic HRT.1

Blissel® 50 micrograms/g vaginal gel is licensed for the treatment of symptoms of vaginal atrophy due to estrogen deficiency in postmenopausal women. Please refer to Summary of Product Characteristics (SmPC) before prescribing. 

Click to visit our bespoke video library, My Blissel, Time to talk

My BlisselⓇ Time to talk
Video Library

A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics, including How Blissel® works, the time until Blissel® takes effect, and how to use an applicator.

Click here to open and play the videos

Women need support and treatment guidance

Blissel® is formulated as a mucoadhesive gel, using specialist polycarbophylic ingredients, which leads to a moisturising effect, whilst also making sure that the active hormone is not lost.2

Products not formulated with mucoadhesive ingredients may end up being in contact with the vaginal tissue for a shorter time and may lead to leakage.2

The British Menopause Society advocates the lowest HRT dose that will effectively manage a patient’s symptoms should be prescribed for vaginal atrophy.3

Formulations that contain a low dose of estriol, such as Blissel®, can lead to lower systemic absorption.4

How treatment formulation may affect patient experience

Blissel 50 micrograms/g vaginal gel

By using specialist polycarbophylic ingredients, Blissel® is formulated as a mucoadhesive gel, delivering a moisturising effect and also ensuring that the active hormone is not lost.2

Using non-mucoadhesive products may lead to a shorter contact time with the vaginal tissue and may cause leakage.2

Guidelines advocating to use the lowest HRT dose that will effectively manage a patient’s VA symptoms have been produced by The British Menopause Society.3

Lower systemic absorption may be achieved by using formulations that contain a low dose of estriol, such as Blissel®.4

Prescribing and adverse event reporting information can be found at the end of this video.

Click to play our Benefits of a gel video
Click to watch our Benefits of a gel video.

Using Blissel® to treat vaginal atrophy

Click to play our Time until Blissel takes effect video
Click to play our Time until Blissel takes effect video.

Prescribing and adverse event reporting information can be found at the end of this video.

Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, which is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.1,5

For postmenopausal vaginal atrophy, Blissel® has been shown to be an effective treatment for postmenopausal women with VA1,5 and may give your patient rapid symptom improvement from the first days of treatment.2

Prescribe Blissel® by brand for your patients to ensure the gel is not replaced when it is dispensed.

Blissel® is the first and only prescribable estriol containing gel specifically for the treatment of vaginal atrophy.1,5

Please refer to safety information below.

Upcoming Webinars 2026

Our next FREE ONLINE Webinar is on 14th April 2026 between 7.30 – 9.30 pm

More information will be available soon.

Click Here To Find Out More

How BlisselⓇ
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel1,5

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

  1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
  2. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.
  3. British Menopause Society Women’s Health Concern Fact Sheet: HRT Benefits and Risks; Nov 2022.
  4. Delgado JL, et al. Climacteric. 2016;19(2):172-80.
  5. Cano A, et al. Menopause. 2012;19(10):1130-9.

Date of preparation: February 2026 | UK-BLS-614(3)

BlisselⓇ (Estriol 50 Micrograms/G Vaginal Gel)
Safety Information:

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1


Date of preparation: April 2026 Item code: UK-BLS-671(1)